Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Janssen Licenses Genmab Cancer Drug
by Lisa M. Jarvis
September 10, 2012
| A version of this story appeared in
Volume 90, Issue 37
Janssen Biotech, an arm of Johnson & Johnson, will pay Genmab $55 million up front for access to the monoclonal antibody daratumumab and a backup antibody. As part of the deal, J&J will invest roughly $80 million in the Danish biotech company. Janssen will also take on development costs for daratumumab, including paying for ongoing Phase I/II clinical trials in patients with multiple myeloma. Daratumumab binds to CD38, a protein on the surface of several kinds of immune cells.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter